戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 receiving treatment (less than one-third of those estimated to be eligible).
2 ded at least one PMT visit within 12 months were determined to be eligible.
3 rmance status of 0 or 1, and at least one measurable lesion to be eligible.
4                          The NPAO patients were less likely to be eligible after 9 hours than before 9 hours (17% for >9
5 ts (OR, 0.56; 95% CI, 0.38-0.82; P = .003) were less likely to be eligible after screening visit 1.
6                            A total of 33 studies were found to be eligible and included 3 matched case control studies an
7                   We screened 1193 patients; 178 were found to be eligible and were randomly assigned to treatment groups
8                    A total of 2,384 persons were determined to be eligible, and 2,041 (85.6%) were examined.
9 o hundred eighty-five (86%) of the patients were determined to be eligible, and 47 (14%) were not eligible.
10 p performance status of 0-2, at least one measurable lesion to be eligible, and who were ineligible for intensive chemoth
11 or further interventions, 9 were certified and 9 were found to be eligible, but declined certification.
12 y 11.9% of ICA+ but GAA- and ICA512AA- relatives were found to be eligible by DPT criteria for trial entry.
13 t of rapid ART initiation specifically among patients known to be eligible for ART before treat all.
14 n identified 60% of the patients with sinus venosus defects to be eligible for catheter closure.
15                                                             To be eligible for enrollment, patients had to meet one of th
16 nfection, be younger than 28 days, and required HIV testing to be eligible for enrolment.
17 d medical conditions, blacks were significantly less likely to be eligible for HCV treatment.
18 dividuals) and 13 MN studies (2,097 individuals) were found to be eligible for inclusion in a meta-analysis.
19                                                             To be eligible for inclusion in the final analysis, a dataset
20             Of 110 studies identified, 25 trials were shown to be eligible for inclusion in the meta-analysis.
21                                                             To be eligible for inclusion, individuals must have been judg
22                                                             To be eligible for inclusion, participants had to have at lea
23                                                             To be eligible for inclusion, participants had to have had de
24                                                             To be eligible for inclusion, the material needed to have inf
25 d OR = 0.15; 95% CI: 0.09, 0.24; P < .001) were less likely to be eligible for LCS under previous guidelines.
26  as racial and ethnic minority groups are still less likely to be eligible for lung cancer screening.
27 lt travelers were included; providers considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consu
28                   Of 560 volunteers screened, 71 were found to be eligible for participation.
29     Racial/ethnic minorities were significantly less likely to be eligible for screening yet had higher odds of developin
30 participate in the study; 1,375 APA members were determined to be eligible for study participation.
31 up I patients had smaller tumors (P =.01), were more likely to be eligible for surgical treatment (P =.005), and had a be
32                                                             To be eligible for the en face OCT subanalysis, the preserved
33                                                             To be eligible for the oral insulin trial, a relative had to
34                                                             To be eligible for the parenteral insulin DPT-1 trial, a rela
35                                                             To be eligible for the review, studies had to describe and re
36                                                             To be eligible for the trial, patients have to have exhausted
37  All subjects had to have a diagnosis of colorectal adenoma to be eligible for the trial.
38  basis of confirmatory echocardiography and were determined to be eligible for the trial.
39 ype 1 infection, blacks were 65% less likely than nonblacks to be eligible for treatment (28.1% > 17.0%; relative risk, 1
40 h frontline nivolumab who were clinically stable and judged to be eligible for treatment beyond RECIST v1.1-defined progr
41 ing is provision of real-world estimates of patients likely to be eligible for triaging, but these are challenging to obt
42                                      Of 572 relatives found to be eligible for trial entry, 442 (77.3%) were positive for
43                                                             To be eligible, participants needed to have access to the int
44                                                             To be eligible, patients had have an Eastern Cooperative Onco
45                                                             To be eligible, patients had to be aged at least 18 years and
46                                                             To be eligible, studies had to meet three inclusion criteria:
47                                                    However, to be eligible, these patients generally must have a prognosi
48                                               For a patient to be eligible, tissue microarrays, clinical follow-up data,
49 d OR = 0.15; 95% CI: 0.10, 0.23; P < .001) were less likely to be eligible under the revised guidelines.
50                                                             To be eligible, women had to be at increased risk of breast c